V Möbus1, C Jackisch2, H J Lück3, A du Bois4, C Thomssen5, W Kuhn6, U Nitz7, A Schneeweiss8, J Huober9, N Harbeck10, G von Minckwitz11, I B Runnebaum12, A Hinke13, G E Konecny14, M Untch15, C Kurbacher16. 1. Department of Gynecology and Obstetrics, Klinikum Frankfurt Höchst, Frankfurt, Germany. 2. Department of Gynecology and Obstetrics, Sana Klinikum Offenbach GmbH, Offenbach am Main, Germany. 3. Gynecologic Oncology Practice, Hannover, Germany. 4. Department of Gynecology & Gynecologic Oncology, Klinikum Essen-Mitte, Essen, Germany. 5. Department of Gynecology, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany. 6. Department of Gynecology and Obstetrics, University of Bonn, Bonn, Germany. 7. Breast Center Niederrhein, Evangelic Hospital Bethesda, Mönchengladbach, Germany. 8. National Centre of Tumor Diseases, University of Heidelberg, Heidelberg, Germany. 9. Department of Gynecology and Obstetrics, University of Ulm, Ulm, Germany. 10. Department of Gynecology and Obstetrics, University of Munich, Munich, Germany. 11. German Breast Group, Neu-Isenburg, Germany. 12. Department of Gynecology, University of Jena, Jena, Germany. 13. WiSP Research Institute, Langenfeld, Germany. 14. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA. 15. Department of Gynecology and Obstetrics, Helios Klinikum Berlin-Buch, Berlin, Germany. 16. Medical Center, Bonn-Friedensplatz, Bonn, Germany.
Abstract
Background: Primary breast cancer (BC) patients with extensive axillary lymph-node involvement have a limited prognosis. The Arbeitsgemeinschaft fuer Gynaekologische Onkologie (AGO) trial compared intense dose-dense (idd) adjuvant chemotherapy with conventionally scheduled chemotherapy in high-risk BC patients. Here we report the final, 10-year follow-up analysis. Patients and methods: Enrolment took place between December 1998 and April 2003. A total of 1284 patients with 4 or more involved axillary lymph nodes were randomly assigned to receive 3 courses each of idd sequential epirubicin, paclitaxel and cyclophosphamide (iddEPC) q2w or standard epirubicin/cyclophosphamide followed by paclitaxel (EC → P) q3w. Event-free survival (EFS) was the primary end point. Results: A total of 658 patients were assigned to receive iddEPCand 626 patients were assigned to receive EC → P. The median duration of follow-up was 122 months. EFS was 47% (95% CI 43% to 52%) in the standard group and 56% (95% CI 52% to 60%) in the iddEPC group [hazard ratio (HR) 0.74, 95% CI 0.63-0.87; log-rank P = 0.00014, one-sided]. This benefit was independent of menopausal, hormone receptor or HER2 status. Ten-year overall survival (OS) was 59% (95% CI 55% to 63%) for patients in the standard group and 69% (95% CI 65% to 73%) for patients in the iddEPC group (HR = 0.72, 95% CI 0.60-0.87; log-rank P = 0.0007, two-sided). Nine versus two cases of secondary myeloid leukemia/myelodysplastic syndrome were observed in the iddEPC and the EC → P arm, respectively. Conclusion: The previously reported OS benefit of iddEPC in comparison to conventionally dosed EC → P has been further increased and achieved an absolute difference of 10% after 10 years of follow-up.
RCT Entities:
Background: Primary breast cancer (BC) patients with extensive axillary lymph-node involvement have a limited prognosis. The Arbeitsgemeinschaft fuer Gynaekologische Onkologie (AGO) trial compared intense dose-dense (idd) adjuvant chemotherapy with conventionally scheduled chemotherapy in high-risk BC patients. Here we report the final, 10-year follow-up analysis. Patients and methods: Enrolment took place between December 1998 and April 2003. A total of 1284 patients with 4 or more involved axillary lymph nodes were randomly assigned to receive 3 courses each of idd sequential epirubicin, paclitaxel and cyclophosphamide (iddEPC) q2w or standard epirubicin/cyclophosphamide followed by paclitaxel (EC → P) q3w. Event-free survival (EFS) was the primary end point. Results: A total of 658 patients were assigned to receive iddEPC and 626 patients were assigned to receive EC → P. The median duration of follow-up was 122 months. EFS was 47% (95% CI 43% to 52%) in the standard group and 56% (95% CI 52% to 60%) in the iddEPC group [hazard ratio (HR) 0.74, 95% CI 0.63-0.87; log-rank P = 0.00014, one-sided]. This benefit was independent of menopausal, hormone receptor or HER2 status. Ten-year overall survival (OS) was 59% (95% CI 55% to 63%) for patients in the standard group and 69% (95% CI 65% to 73%) for patients in the iddEPC group (HR = 0.72, 95% CI 0.60-0.87; log-rank P = 0.0007, two-sided). Nine versus two cases of secondary myeloid leukemia/myelodysplastic syndrome were observed in the iddEPC and the EC → P arm, respectively. Conclusion: The previously reported OS benefit of iddEPC in comparison to conventionally dosed EC → P has been further increased and achieved an absolute difference of 10% after 10 years of follow-up.
Authors: Jana de Boniface; Marcus Schmidt; Jutta Engel; Marjolein L Smidt; Birgitte Vrou Offersen; Toralf Reimer Journal: Breast Care (Basel) Date: 2018-09-05 Impact factor: 2.860
Authors: Gun Min Kim; Joo Hoon Kim; Ji Heung Kim; Young Up Cho; Seung Il Kim; Seho Park; Hyung Seok Park; Ji Ye Kim; Joohyuk Sohn Journal: Cancer Res Treat Date: 2018-09-19 Impact factor: 4.679
Authors: Diana Lüftner; Andreas Schneeweiss; Andreas D Hartkopf; Volkmar Müller; Achim Wöckel; Wolfgang Janni; Johannes Ettl; Erik Belleville; Florian Schütz; Marc Thill; Jens Huober; Peter A Fasching; Hans-Christian Kolberg; Patrik Pöschke; Manfred Welslau; Friedrich Overkamp; Hans Tesch; Tanja N Fehm; Michael P Lux Journal: Geburtshilfe Frauenheilkd Date: 2020-04-21 Impact factor: 2.915
Authors: Neha Pathak; Aparna Sharma; Arunmozhimaran Elavarasi; Jeeva Sankar; S V S Deo; Daya N Sharma; Sandeep Mathur; Sudhir Kumar; Chandra P Prasad; Akash Kumar; Atul Batra Journal: Breast Date: 2022-04-15 Impact factor: 4.254